Adaptimmune Hits High With TCR Platform Success With GSK Licensed Product
Executive Summary
The T-cell therapy company has been tipped as a potential leader in a potentially disruptive field as new data support wide application in cancer.
You may also be interested in...
Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.
J.P. Morgan 2019: Biopharma Sentiment Soars As Deal And Financing Optimism Abounds
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
Quality Expert Urges Firms To Adopt QbD Approach When Developing Cell Therapies
Expert explains how firms can leverage pharmaceutical quality-by-design principles when developing cell therapies to help make sure their manufacturing processes remain in a state of control over the product lifecycle.